Table 2

Treatment response

ResponseInitial treatment
Crossover treatment
Dasatinib; N = 101
High-dose imatinib; N = 49
From high-dose imatinib to dasatinib; N = 39*
From dasatinib to high-dose imatinib; N = 15*
%95% CI%95% CI%95% CI%95% CI
Complete hematologic response 93 86.2-97.2† 82 68.0-91.2 92 79.1-98.4‡ 53 26.6-78.7 
Cytogenetic response 
    Major 52 42.3-62.5§ 33 19.9-47.5 45 28.6-61.7‖ 15 1.9-45.4 
    Complete 40 30.0-49.8 16 7.3-29.7 29 15.4-45.9# 0 0-25.7 
    Partial 13 7.0-21.0 16 7.3-29.7 16 6.0-31.3 15 1.9-45.4 
Major molecular response 16 9.3-24.4** 4 0.5-14.0 NA NA NA NA 
ResponseInitial treatment
Crossover treatment
Dasatinib; N = 101
High-dose imatinib; N = 49
From high-dose imatinib to dasatinib; N = 39*
From dasatinib to high-dose imatinib; N = 15*
%95% CI%95% CI%95% CI%95% CI
Complete hematologic response 93 86.2-97.2† 82 68.0-91.2 92 79.1-98.4‡ 53 26.6-78.7 
Cytogenetic response 
    Major 52 42.3-62.5§ 33 19.9-47.5 45 28.6-61.7‖ 15 1.9-45.4 
    Complete 40 30.0-49.8 16 7.3-29.7 29 15.4-45.9# 0 0-25.7 
    Partial 13 7.0-21.0 16 7.3-29.7 16 6.0-31.3 15 1.9-45.4 
Major molecular response 16 9.3-24.4** 4 0.5-14.0 NA NA NA NA 

CI indicates confidence interval; NA, not applicable.

*

Fifty-one patients were evaluable for cytogenetic response postcrossover (dasatinib, 38; imatinib, 13). Statistically significant differences between treatments:

†

P = .034.

‡

P = .001.

§

P = .023.

‖

P = .063.

P = .004.

#

P = .031.

**

P = .038.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal